ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
- Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 - - Pre-clinical studies...








